GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports purchases of its ordinary shares under its ongoing buyback programme. On 28 August 2025 the company, acting through broker Merrill Lynch International, acquired 236,167 ordinary shares of 31.25 pence each with a reported lowest price of 1,460.50p, highest price of 1,479.00p and an average/aggregate price shown as 1,466.11p. The purchased shares will be held as treasury shares and the announcement confirms this forms part of the non-discretionary agreement with the broker entered into on 4 June 2025. Since that agreement the Company has purchased 26,021,500 ordinary shares. After the 28 August purchase GSK will hold 244,155,883 shares in treasury and have 4,071,236,744 ordinary shares in issue (excluding treasury), giving a total number of voting rights of 4,071,236,744 and treasury shares representing 6.00% of voting rights. Detailed trade-level execution data across the London Stock Exchange and CBOE Europe are included.
GSK plc purchased 260,986 ordinary shares on 27 August 2025 through Merrill Lynch International as part of its existing buyback programme. The trades were executed on the London Stock Exchange (and reported across recognised venues) at prices between 1,471.00p and 1,484.00p, with an aggregated average price reported as 1,477.76p. Since the non-discretionary broker agreement of 4 June 2025, the Company has bought 25,785,333 ordinary shares. After this transaction GSK will hold 243,919,716 shares in treasury and will have 4,071,472,911 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,071,472,911, and treasury shares represent 5.99% of voting rights.
GSK plc reports that, acting through Merrill Lynch International, it purchased 251,452 ordinary shares of 31.75p each on 26 August 2025 under its ongoing buyback programme. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased a total of 25,524,347 ordinary shares. Following the latest purchase the Company will hold 243,658,730 ordinary shares in treasury and have 4,071,733,897 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,071,733,897, and the percentage of voting rights attributable to treasury shares is reported as 5.98%.
GSK plc reports on 22 August 2025 that, acting through its corporate broker Merrill Lynch International under a non-discretionary agreement entered into on 4 June 2025, it purchased 243,639 ordinary shares for holding as Treasury shares as part of its existing buyback programme. Since 4 June 2025 the company has purchased a total of 25,272,895 ordinary shares. After this purchase GSK will hold 243,407,278 ordinary shares in treasury and have 4,071,985,349 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,071,985,349 and the percentage of voting rights attributable to ordinary shares held in treasury is 5.98%.
GSK plc reported a share purchase under its ongoing buyback programme. On 21 August 2025 the Company, acting through Merrill Lynch International, bought 238,918 ordinary shares of 31.75 pence each at prices between 1,473.00p and 1,492.00p, with individual trades listed at execution prices around 1,474p–1,486p. These shares will be held as Treasury shares.
Since the non-discretionary broker agreement dated 4 June 2025, GSK has purchased 25,029,256 ordinary shares. After the 21 August purchase the Company holds 243,163,639 ordinary shares in treasury and has 4,072,228,095 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,072,228,095 and the percentage of voting rights attributable to ordinary shares held in treasury is 5.97%.
GSK plc filed a Form 6-K reporting a transaction notification dated August 21, 2025. The notice identifies the security by ISIN US37733W2044 and discloses an aggregated traded volume of 2,501.842 (shares/units as stated). The filing indicates the company files annual reports on Form 20-F. The document does not provide a transaction price, counterparty, or the exact nature of the trade beyond the aggregated volume and ISIN, so further detail about value or economic impact is not available from the text provided.
GSK plc reports that, acting through Merrill Lynch International, it purchased 214,694 ordinary shares of 31.25p each on 20 August 2025 as part of its ongoing buyback programme under the non-discretionary broker agreement dated 4 June 2025. Since 4 June 2025 the Company has purchased 24,790,338 ordinary shares. The purchased shares will be held as Treasury shares bringing the total held in treasury to 242,924,721. The Company has 4,072,467,013 ordinary shares in issue excluding Treasury shares and the total number of voting rights is 4,072,467,013. The percentage of voting rights attributable to treasury shares is 5.97%.
GSK plc reported a purchase of 211,358 ordinary shares of 31.75p each on 19 August 2025 under its announced buyback programme executed by Merrill Lynch International. The shares will be held as treasury stock. Since the non-discretionary broker agreement dated 4 June 2025, the Company has bought 24,575,644 ordinary shares. After this transaction GSK will hold 242,710,027 shares in treasury and will have 4,072,681,707 ordinary shares in issue (excluding treasury), giving a total voting rights denominator of 4,072,681,707 and treasury shares representing 5.96% of voting rights. The filing lists detailed trade-by-trade prices and venues for the aggregated purchases.
GSK plc submitted a Form 6-K reporting a transaction notification dated August 19, 2025. The filing identifies the security by ISIN US37733W2044 and lists three reported volumes: 3,328.441, 84, and 61.934. The report does not disclose prices, counterparty names, or the specific nature of each transaction in the supplied text. No financial amounts, proceeds, gains, or other narrative explanation appear in the provided content. Because key fields such as price and transaction description are not present, the filing records activity in the listed share lots but provides limited information to assess material investor impact.
GSK plc reported a transaction in its ordinary shares on 18 August 2025 under its ongoing buyback programme. Acting through Merrill Lynch International, the Company purchased 221,293 ordinary shares at prices shown in the schedule, with an average price reported as 1,437.72p. The purchased shares will be held as Treasury shares.
Since entering the non-discretionary broker agreement on 4 June 2025, GSK has bought 24,364,286 ordinary shares. After this trade GSK will hold 242,498,669 shares in treasury and will have 4,072,893,065 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,072,893,065 and treasury shares represent 5.95% of voting rights.